Trial reportEuropean journal of nuclear medicine and molecular imaging2024
Evaluation of the safety, biodistribution, dosimetry of [
Trial report in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06056362 (Evaluation of Biodistribution, Dosimetry, Diagnostic Ability, and Safety of Al18F-NOTA-LM3 in Patients With Well-differentiated Neuroendocrine Tumors, and Comparison With 68Ga-DOTATATE and 68Ga-NODAGA-LM3), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Biodistribution, Dosimetry, Diagnostic Ability, and Safety of Al18F-NOTA-LM3 in Patients With Well-differentiated Neuroendocrine Tumors, and Comparison With 68Ga-DOTATATE and 68Ga-NODAGA-LM3: A Prospective, Single-center, Double-blinded Study
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Assessment of the diagnostic efficacy and clinical significance of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Beyond tumor tracing: physiological uptake of sympathetic ganglia on somatostatin receptor PET/CT - prevalence, patterns, and biological rationale.European journal of nuclear medicine and molecular imaging · 2026Article
- Beyond DOTATATE: [European journal of nuclear medicine and molecular imaging · 2026Article
- Head-to-Head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals for the localization pulmonary metastasis in a papillary thyroid tumour patient.European journal of nuclear medicine and molecular imaging · 2025Article
- Tumor-induced osteomalacia secondary to phosphaturic mesenchymal tumor: a case description and literature analysis.Quantitative imaging in medicine and surgery · 2025Article
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
- Research process of PET tracers for neuroendocrine tumors diagnosis.American journal of nuclear medicine and molecular imaging · 2025Review
- Feasibility of a deep-inspiration breath-hold [EJNMMI physics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purpose
methodsTwenty-one patients with histologically confirmed well-differentiated neuroendocrine tumors (G1 and G2) were prospectively recruited. The first eight patients underwent serial PET scans at 5, 15, 30, 45, 60, and 120 min after [
results[
conclusion[
trial registrationClinicalTrials.gov identifier NCT06056362.
Indexed as
Identifiers
38878175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.